Allergan plc (NYSE:AGN) appreciated by 1.28% at $174.41. Allergan plc has 334.11 million shares outstanding, and in the last trade has seen ATR around 5.52. The volume of AGN witnessed a shift from 2.53 million shares, based on a 50-day average, to 3.48 million shares.

In the most updated research from a number of analysts on Wall Street, the company gets 12 Buys and 0 Sell among 20 analysts. Allergan plc (NYSE:AGN) hasconsensus analyst target price is $230.78. That gives us a street projected return of 32.32%. If the published price targets set by Allergan plc analysts have any power to influence the stock’s share price, the highest price target set for AGN is $280.

Allergan plc most recently reported earnings per share (EPS) of $4.15 for the September 2017 versus $3.32 in the same quarter last year, representing 25% growth. Analysts had predicted $4.05. Revenue during the quarter was $4.03 billion, representing 11% growth from $3.62 billion in year-ago quarter. The company’s quarterly EPS surprised Wall Street by as much as 2% to the upside in its last earnings announcement, so investors should note this tendency when assessing consensus estimates.

On a similar note, analysts expect EPS of $4.73 in December 2017 quarter and $3.74 in March 2018 quarter, representing 21.28% and 11.64% growth, respectively. They expect this year’s earnings to rise 20.5% year-over-year to $16.28, followed by 0% decline in the next year to $16.28.

Shares of Emerson Electric Co. (NYSE:EMR) traded down -0.36% in the last session while performance was up 61.39% in the last five days. The stock’s last price was lower from the average trading price of 50 days recorded at $63.49 while enlarging the period to 200 trading days, the average price was $60.66. Currently, 638.67 million total shares are owned by the public and among those 636.15 million shares have been available to trade. The percentage of shares being held by the company management was 0.5% while institutional stake was 71.7%.

Emerson Electric Co. (EMR) has risen 13.85% since then. But since then, those gains have faded by -9.43%. EMR has lost -4.03% in the 1-month period.

Allergan plc has a beta of 1.25, offering the possibility of a higher rate of return, but also posing more risk. The portion of a company’s profit allocated to each outstanding share of common stock was $2.56 a share in the trailing twelve months. It last reported revenues of $4.44 billion and EPS of $0.83 for the September 2017, representing -19% top-line growth and 0.96 EPS growth.

Looking forward, the company’s quarterly earnings are expected to come at $0.53 in the three months through December 2017 and $0.68 in the quarter ending March 2018, reflecting 8.16% and 17.24% growth, respectively. For the full year, analysts expect earnings to jump 9.85% yoy to $2.9. Next year this growth will reach 11.03% to attain $3.22.